AN ACT RELATING TO INSURANCE -- BENEFIT DETERMINATION AND UTILIZATION REVIEW ACT

HB 5024 prohibits health insurers from requiring or conducting utilization reviews for prescriptions used to treat opioid or alcohol use disorders. Specifically, it bans reviews for prescriptions containing Methadone, Buprenorphine, or Naltrexone, or those approved by the FDA to mitigate opioid withdrawal symptoms. The bill directly affects individuals receiving medication-assisted treatment for addiction and insurers who would otherwise review these prescriptions. It ensures coverage for these treatments cannot be denied after prior approval, unless fraud or misrepresentation occurred. The law takes effect upon passage.